Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3 Genitourinary 2 Tumor-Agnostic 1 Lymphoid 1 Gynecologic 1 CNS 1

Conditions

Recurrence 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1

Interventions

Cyclophosphamide 211 Rituximab 193 fludarabine 134 fludarabine phosphate 91 Vincristine 78 Cytarabine 66 Etoposide 65 Doxorubicin 61 Dexamethasone 60 Lenalidomide 59 venetoclax 56 ibrutinib 55 Prednisone 54 Bendamustine Hydrochloride 51 obinutuzumab 48 Filgrastim 46 Bortezomib 46 Specimen Handling 42 pembrolizumab 39 Gemcitabine 39 Methotrexate 38 Melphalan 38 Biopsy 38 Peripheral Blood Stem Cell Transplantation 32 Magnetic Resonance Spectroscopy 32 Azacitidine 31 Vorinostat 29 Nivolumab 29 Calcium Dobesilate 29 Clofarabine 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × vistusertib × Lymphoid × Clear all

NCT02780830 2016-09-15

INHIBITOR

AstraZeneca

Phase 1 Withdrawn

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡